(R)-3-Pyrrolidinol → HCID 44545043, 화합물
반응식
C(OC([NH:8][C:9]1[N:14]=[CH:13][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][CH2:25][C:26](O)=[O:27])=[C:17]([N:29]3[CH2:34][CH2:33][O:32][CH2:31][CH2:30]3)[N:16]=2)=[CH:11][N:10]=1)=O)(C)(C)C.[NH:35]1[CH2:39][CH2:38][C@@H:37]([OH:40])[CH2:36]1>>[NH2:8][C:9]1[N:10]=[CH:11][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][CH2:25][C:26]([N:35]3[CH2:39][CH2:38][C@@H:37]([OH:40])[CH2:36]3)=[O:27])=[C:17]([N:29]3[CH2:34][CH2:33][O:32][CH2:31][CH2:30]3)[N:16]=2)=[CH:13][N:14]=1참가 물질
3
실험 절차
3-(2-(2-(Tert-butoxycarbonylamino)pyrimidin-5-yl)-6-morpholino-9H-purin-9-yl)propanoic acid (50 mg) was reacted with (R)-pyrrolidin-3-ol via General Procedure F followed by Boc deprotection via General Procedure E to give 10.9 mg 109 as white solid following reverse phase purification. MS (Q1) 440.2 (M)+
후처리
- customto give
- custom10.9 mg 109 as white solid following reverse phase purification
출처 및 근거
- ORD 기록
- ord-ebc8890fba11485c92dccb368eed02bb
- 출처 데이터셋
- uspto-grants-2012_04
- 특허 번호
- US08158624B2
반응 노트
불러오는 중…